QURE insider buying and SEC filings, explained
uniQure N.V. · CIK 1590560
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
- Former names
- uniQure B.V.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$2.3M
Planned sales (10b5-1)
$19.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 2, 2026 | Planned (10b5-1) | Matthew C Kapusta (CEO and Director) sold 21,082 shares at about $45.16 ($952K), marked as a 10b5-1 plan trade. Holdings down 4% to 519,227 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Walid Abi-Saab (Chief Medical Officer) sold 30,000 shares at about $46.42 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 17% to 148,235 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Jack Kaye (Director) sold 21,167 shares at about $46.44 ($983K), marked as a 10b5-1 plan trade. Holdings down 45% to 25,996 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 26, 2026 | Sale | Walid Abi-Saab (Chief Medical Officer) sold 1,434 shares at about $46.86 ($67K). Holdings down 1% to 168,235 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 30, 2026 |
| Jun 24–25, 2026 | Planned (10b5-1) | Matthew C Kapusta (CEO and Director) sold 35,412 shares between Jun 24 and Jun 25 at about $50.02 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 6% to 519,227 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 17–18, 2026 | Planned (10b5-1) | Matthew C Kapusta (CEO and Director) sold 206,100 shares between Jun 17 and Jun 18 at about $45.47 ($9.4M), marked as a 10b5-1 plan trade. Holdings down 28% to 521,795 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Madhavan Balachandran (Director) sold 11,685 shares at about $45.06 ($526K), marked as a 10b5-1 plan trade. Holdings down 21% to 43,254 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Jack Kaye (Director) sold 5,295 shares at about $42.57 ($225K), marked as a 10b5-1 plan trade. Holdings down 17% to 25,996 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Madhavan Balachandran (Director) sold 10,000 shares at about $27.85 ($279K), marked as a 10b5-1 plan trade. Holdings down 19% to 43,254 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 15, 2026 | Sale | Jeannette Potts (Chief Legal Officer) sold 5,237 shares at about $27.67 ($145K). Holdings down 4% to 133,246 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 11, 2026 | Sale | Kylie O'Keefe (Chief Customer & Strat Officer) sold 15,936 shares at about $27.06 ($431K). Holdings down 13% to 108,864 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | David D. Meek (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 5% to 39,747 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 10–11, 2026 | Planned (10b5-1) | Robert Gut (Director) sold 10,278 shares between Jun 10 and Jun 11 at about $26.32 ($270K), marked as a 10b5-1 plan trade. Holdings down 24% to 32,259 shares. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | Jeremy P. Springhorn (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 4% to 43,251 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | Leonard E. Post (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 5% to 35,494 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | Jack Kaye (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 7% to 25,996 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | Rachelle Suzanne Jacques (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 6% to 33,903 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 11, 2026 | Sale | Madhavan Balachandran (Director) sold 1,993 shares at about $27.06 ($54K). Holdings down 4% to 43,254 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 12, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Jack Kaye (Director) sold 2,645 shares at $30.01 ($79K), marked as a 10b5-1 plan trade. Holdings down 11% to 20,439 shares. | SEC filing Filed Jun 5, 2026 |
| May 8, 2026 | Planned (10b5-1) | Walid Abi-Saab (Chief Medical Officer) sold 45,000 shares at about $25.06 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 21% to 169,669 shares. | SEC filing Filed May 12, 2026 |
| Mar 4, 2026 | Sale | Matthew C Kapusta (CEO and Director) sold 14,581 shares at about $9.06 ($132K). Holdings down 2% to 660,658 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Walid Abi-Saab (Chief Medical Officer) sold 808 shares at about $9.06 ($7K). Holdings down <1% to 189,669 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Jeannette Potts (Chief Legal Officer) sold 3,412 shares at about $9.06 ($31K). Holdings down 2% to 138,483 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Christian Klemt (CFO) sold 12,000 shares at about $9.06 ($109K). Holdings down 5% to 226,581 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Sale | Matthew C Kapusta (CEO and Director) sold 34,437 shares at about $9.95 ($343K). Holdings down 5% to 604,639 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Christian Klemt (CFO) sold 12,532 shares at about $9.95 ($125K). Holdings down 6% to 198,981 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Jeannette Potts (Chief Legal Officer) sold 8,578 shares at about $9.95 ($85K). Holdings down 7% to 106,495 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Walid Abi-Saab (Chief Medical Officer) sold 1,660 shares at about $9.95 ($17K). Holdings down 1% to 148,777 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 25, 2026 | Sale | Matthew C Kapusta (CEO and Director) sold 12,378 shares at about $23.86 ($295K). Holdings down 2% to 639,076 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 27, 2026 |
| Feb 25, 2026 | Sale | Christian Klemt (CFO) sold 6,217 shares at about $23.86 ($148K). Holdings down 3% to 211,513 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 27, 2026 |
| Jan 12, 2026 | Planned (10b5-1) | Robert Gut (Director) sold 25,613 shares at about $24.62 ($630K), marked as a 10b5-1 plan trade. Holdings down 44% to 32,342 shares. | SEC filing Filed Jan 14, 2026 |
| Jan 9, 2026 | Planned (10b5-1) | Jack Kaye (Director) sold 6,390 shares at about $27.28 ($174K), marked as a 10b5-1 plan trade. Holdings down 24% to 20,439 shares. | SEC filing Filed Jan 12, 2026 |
| Nov 6, 2025 | Planned (10b5-1) | Robert Gut (Director) sold 31,434 shares at about $27.26 ($857K), marked as a 10b5-1 plan trade. Holdings down 44% to 40,145 shares. | SEC filing Filed Nov 10, 2025 |
| Nov 4, 2025 | Planned (10b5-1) | Jack Kaye (Director) sold 38,810 shares at about $30.34 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 66% to 20,439 shares. | SEC filing Filed Nov 6, 2025 |
27 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 7:15 AM ET 8-K | Reg FD disclosure (Item 7.01) Other event (Item 8.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow QURE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.